Table 1 Demographic and clinical attributes of the 20 patients
ALL patients | sEBR | |||
|---|---|---|---|---|
(n = 20) | Increase (n = 9) | Unchanged (n = 3) | Decrease (n = 6) | |
Age (years old) | 63.05 (9.41) | 60.8 (8.9) | 73.7 (4.7) | 60.3 (9.5) |
Gender (n) | Male 11, Female9 | Male 5, Female 4 | Male 2, Female 1 | Male 4, Female 2 |
Body Mass Index | 23.59 (5.25) | 23.0 (3.4) | 22.9 (3.2) | 23.94 (6.19) |
Disease Duration (years) | 12.2 (6.61) | 14.4 (9.0) | 9.3 (0.5) | 10 (4.1) |
MMSE | 28.75 (1.92) | 28.7 (2.7) | 28.3 (0.6) | 28.7 (1.2) |
EQ-5D-5L | 58.5 (19.47) | 56.7 (15.6) | 55 (25) | 57.5 (24.2) |
PDQ-39 SI | 31.11 (16.60) | 30.7 (12.1) | 18.0 (9.7) | 31.16 (16.43) |
LEDD (mg) | 1055.73 (384.0) | 1076.5 (296.7) | 800.0 (180.3) | 1136.0 (566.2) |
Hoehn Yahr at on state | 2.2 (0.41) | 2.2 (0.4) | 2.3 (0.6) | 2.2 (0.4) |
Hoehn Yahr at off state | 2.5 (0.76) | 2.6 (0.5) | 2.3 (0.6) | 2.5 (1.2) |
MDS-UPDRS part I | 12 (3.63) | 11.8 (2.9) | 12.7 (6.4) | 11.5 (4.2) |
MDS-UPDRS part II | 15.75 (6.30) | 14.6 (7.2) | 14.7 (8.5) | 17.2 (5.3) |
MDS-UPDRS part III at on state | 15.8 (6.79) | 12.2 (5.4) | 17 (3.5) | 16.8 (4.1) |
MDS-UPDRS part III at off state | 41.7 (12.37) | 44.6 (15.4) | 32.3 (5.5) | 41.5 (10.9) |
Improvement rate | 60.9 (15.5) | 71.9 (9.3) | 46.9 (10.0) | 58.8 (7.8) |
MDS-UPDRS part IV | 7.65 (3.33) | 8.1 (3.3) | 5.7 (1.5) | 8.5 (4.3) |
UDysRS | 12.3 (13.1) | 12.9 (13.7) | 6.7 (11.5) | 16.5 (18.2) |
Test drug | ||||
Levodopa/Carbidopa (n) | 17 | 7 | 3 | 6 |
Levodopa/Benserazide (n) | 3 | 2 | 0 | 0 |
Levodopa dose (mg) | 147.5 (52.5) | 138.9 (48.6) | 183.3 (76.4) | 141.7 (49.2) |
Dyskinesia | 10 (50%) | 6 (66.7%) | 1 (33.3%) | 3 (50%) |
Improvement rate | 60.9 (15.5) | 71.9 (9.3) | 46.9 (10.0) | 58.8 (7.8) |
PK parameter of levodopa | ||||
Cmax (pmol/ml) | 10637.6 (4832.1) | 12019.0 (4756.2) | 11520.0 (8719.2) | 9482.4 (2846.3) |
Tmax (min.) | 56.25 (39.50) | 46.67 (35.53) | 40 (17.32) | 67.5 (37.65) |
AUC | 15918.1 (6395.2) | 17153.7 (5817.5) | 18768.2 (7354.8) | 15486.7 (6496.0) |
